Companies · Healthtech
MH · India · Healthtech · founded 2021 · https://www.veerahealth.com
Diligence memoA one-page analyst read on Veera Health — recommendation, valuation, rhythm, risks.→Veera Health: limited disclosed financing to assess.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
Veera Health is one of 2138 Healthtech companies tracked from MH, India, on record since 2021. By capital raised it ranks in the long tail (ahead of 8% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
We treat women with Polycystic Ovary Syndrome in India
Veera Health is helping 110M women in India get treated for Polycystic Ovary Syndrome (PCOS). Our app combines evidence-backed therapy with coaching & specialist support for a subscription fee. PCOS is the most common cause of infertility in women, and can lead to diabetes, depression and cancer. Patients spend up to 10 years and thousands of rupees searching for the right treatment, yet 90% are dissatisfied with existing options. With our program, 85% patients report feeling "in control" of their PCOS after just 1 month and are 4-times more likely to complete treatment. The founders, Shobhita (COO) and Shashwata (CEO) got an inside view into this massive need when the former was diagnosed with PCOS. Shashwata studied data science at Yale University, holds an MBA from Wharton, and helped grow Fortune 100 and growth-stage consumer health / product companies at McKinsey. Shobhita studied Biology & Psychology at Tufts University and has worked with leading healthcare companies, such as GlaxoSmithKline, Accenture Life Sciences & UnitedHealth.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
No round amounts on record to chart.
No staged rounds to sequence.
Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 2138 companies in Healthtech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 8% of sector peers (real $). Modeled value above 8% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| No rounds recorded. | |||||
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Veera Health is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| 10x | Healthtech | — | — | — | same sector |
| 1 Health Providence, Inc. | Healthtech | Pre-Seed | $175K | $1.9M | same sector |
| 4C Health Solutions, Inc. | Healthtech | Seed | $1.3M | $1.9M | same sector |
| Aatru Medical LLC | Healthtech | Seed | $5.7M | $336K | same sector |
| Acolyte Health Inc. | Healthtech | Seed | $2.1M | $1.2M | same sector |
| AcQumen Medical, Inc. | Healthtech | Pre-Seed | $341K | $759K | same sector |
| Adentris | Healthtech | — | — | — | same sector |
| Advanta Health Solutions, Inc. | Healthtech | Pre-Seed | $487K | $2.8M | same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Play Health Perimenopause Care Platform | Biotech | — | — | 76% |
| Almond We make it easy to get great ObGyn care in-person and over telehealth | Healthtech | — | — | 74% |
| Loop Health Modern & comprehensive health insurance plan for employees in India | Healthtech | — | — | 72% |
| Ps-Fertility, Inc. | Other Health Care | Seed | $11.0M | 72% |
| Fertility Partners Holdings Inc. | Other Health Care | Pre-Seed | $3.3M | 71% |
| Veris Health Inc. | Biotechnology | Seed | $7.1M | 71% |
| Frontera Health, Inc. | Healthtech | Series A | $40.1M | 71% |
| Veritas Collaborative Holdings, LLC | Other Health Care | Series A | $46.3M | 70% |
See where Veera Health sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Veera Health, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.